News
Media
Conferences
Publications
Events
CME/CE
Resources
Career Center
Subscribe

Your AI-Trained Oncology Knowledge Connection!

Robert Huisden

Articles by Robert Huisden

4 Datopotamab Deruxtecan (Dato-DXd) + Durvalumab (D) as First-Line (1L) Treatment for Unresectable Locally Advanced/ Metastatic Triple-Negative Breast Cancer (a/mTNBC): Updated Results From BEGONIA, a Phase 1b/2 Study

ByJamil Asselah,Cynthia X. Ma, MD, PhD,Zbigniew Nowecki,Robert Huisden,Ross Stewart,Petra Vuković,Peter Schmid, MD

April 28th 2023

Latest Updated Articles

Trending on CancerNetwork

Spotlighting the Top 10 FDA Oncology Approvals in 2025

Ivosidenib Combo Shows Preliminary Activity in IDH1-Mutated AML

What’s New in Hematology/Oncology? Discussing the 2025 ASH Annual Meeting

Nab-Sirolimus Regimens Show Promise in HR+/HER2-Negative Breast Cancer

‘Relatively Low’ AEs Noted With Durvalumab/FLOT in Gastric/GEJ Cancer